Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 10 · below the Ichimoku cloud · RSI 32 · MACD above its signal
None of the 29 investors followed here reported a position in VVOS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VVOS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 30, 2026 | Amman Bradford KOfficer | Stock Award(Grant) at price 0.41 per share. | 250K | $102.50K |
| Mar 30, 2026 | Skaff Michael C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 1.34 per share. | 1.35M | $1.81M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.2 | -13.6 | -15.7 | -32.2 | -12.5 | -35.0 | -9.9 | -52.2 | -24.5 | -4.3 | −93.0% | ||
| 2025 | -7.5 | -12.6 | -17.9 | -0.4 | -14.8 | 30.6 | 37.0 | 0.0 | -28.4 | -16.8 | -12.4 | -10.2 | −52.7% |
| 2024 | -40.8 | -21.2 | -16.9 | -47.6 | -17.4 | 6.2 | 3.6 | 17.8 | -3.7 | -3.4 | 35.3 | 25.8 | −65.5% |
| 2023 | 171.1 | -44.0 | -44.1 | 0.9 | 11.0 | 33.5 | -42.9 | -13.7 | -23.5 | -33.1 | 663.2 | -49.2 | +23.8% |
| 2022 | 9.8 | 35.2 | -19.8 | -35.4 | 17.3 | -36.5 | -10.9 | 7.0 | -47.2 | 10.8 | -30.6 | -19.6 | −82.1% |
| 2021 | 10.7 | 14.8 | -11.6 | 4.7 | -22.6 | -8.0 | -39.0 | 74.2 | -23.2 | -10.1 | -29.8 | -11.8 | −61.9% |
| 2020 | — |
Buy / hold / sell counts
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.